CLINICAL TRIALS AND OBSERVATIONS Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
نویسندگان
چکیده
1Rush University Medical Center, Chicago, IL; 2Florida Cancer Specialists, Fort Myers; 3Weill Medical College of Cornell University, New York, NY; 4Mayo Clinic, Rochester, MN; 5James P. Wilmot Cancer Center, University of Rochester Medical Center, NY; 6Fred Hutchinson Cancer Research Center, Seattle, WA; 7Eisenhower Medical Center, Rancho Mirage, CA; 8Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; 9Dana-Farber Cancer Institute, Boston, MA; 10Stanford University Medical Center, CA; 11Oregon Health and Sciences University, Portland; 12Memorial Sloan-Kettering Cancer Center, New York, NY; 13M. D. Anderson Cancer Center, Houston, TX; 14Celgene, Summit, NJ; and 15H. Lee Moffitt Cancer Center, Tampa, FL
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
The erythropoietic effects of lenalidomide are cytokine dependent, suggesting that the erythroid hematologic improvement (HI-E) rate may be augmented by combined treatment (CT) with recombinant human erythropoietin (rhu-EPO) in myelodysplastic syndrome (MDS). In the present study, we explored the benefits of CT and the relationship between lenalidomide pharmacokinetics and hematologic toxicity ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
1Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 2Southwest Oncology Group (SWOG) Study Statistical Center, Seattle, WA; 3H. Lee Moffitt Cancer Center, Tampa, FL; 4Seattle Cancer Care Alliance, Seattle, WA; 5University of Rochester, Rochester, NY; 6University of Washington, Seattle, WA; 7University of New Mexico Cancer Center, Albuquerque, NM; and 8Fred Hutchinson Ca...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry
The World Health Organization (WHO) classification contributes to refined classification and prognostication of myelodysplastic syndromes (MDSs). Flow cytometry might add significantly to diagnostic and prognostic criteria. Our analysis of bone marrow samples from 50 patients with MDS showed aberrant expression of differentiation antigens in the myelomonocytic lineage. This also accounted for r...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Older patients with acute myeloid leukemia (AML) have limited treatment options and a poor prognosis, thereby warranting novel therapeutic strategies. We evaluated the efficacy of lenalidomide as frontline therapy for older AML patients. In this phase 2 study, patients 60 years of age or older with untreated AML received highdose (HD) lenalidomide at 50 mg daily for up to 2 28-day cycles. If pa...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
1Leukemia Department, University of Texas M. D. Anderson Cancer Center, Houston, TX; 2Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio, TX; 3Stanford University Cancer Center, Stanford, CA; 4University of California at Los Angeles, Los Angeles, CA; 5Division of Hematological Oncology, Roswell Park Cancer Institute, Buffalo, NY; 6Mount Sinai School of Medi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2007